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In this issue of ”Cardiology Journal”, Kosior
et al. [1] report a randomized trial of propafenone
versus quinidine for recent onset atrial fibrillation.
They found that patients assigned to propafenone,
as opposed to quinidine, had a greater chance of con-
verting to sinus rhythm earlier after drug adminis-
tration. Specifically, propafenone 600 mg orally was
compared to quinidine 400 mg initially then 200 mg
every two hours in combination with intravenous
digoxin to prevent a rapid ventricular response due
to the anticholinergic effect of quinidine. Major ad-
verse events were not observed, and minor events,
although relatively common, were not statistically
significantly different in the two arms.
Several groups have popularized a ‘pill in the
pocket’ approach [2] to conversion of atrial fibrilla-
tion; in essence, this means a loading dose of ei-
ther propafenone (600 mg as used in this study) or
flecainide. Success rates of 56% to 83% have been
reported using this methodology; the percentage
success has varied with duration of atrial fibrillation
prior to treatment [3]. Patients with infrequent
episodes that historically either last more than a few
hours, or do not self-terminate, are candidates for
this approach. This strategy obviates the need for
the patient to come to the emergency room or even
call his or her cardiologist. If the patient has infrequent
episodes the ‘pill in the pocket’ regimen spares him
the need to take a preventive antiarrhythmic drug
twice (or more frequently) a day.
Concerns with the ‘pill in the pocket’ strategy,
however, include the potential for proarrhythmia
with a high dose of antiarrhythmic drug given
outside the hospital. Patients should be free of
structural heart disease, atrio-ventricular (AV)
block, Brugada syndrome and coronary disease.
One advantage of the Class IC agents, propafenone
or flecainide, over quinidine is that significant QT
prolongation is very rare. QTc prolongation is
expected with quinidine [4] (and other Class IA
agents such as procainamide or disopyramide)
which block the IKr channel, in addtion to INa
channels, and the absence of it in this study is in
fact somewhat unexpected. Torsades des pointes
is well recognized with these agents as opposed to
the Class Ic agents. On the other hand, the Class Ic
agents may in some cases produce a phenomenon
of 1:1 atrial flutter.
One-to-one atrial flutter can occur due to slow-
ing of the flutter cycle length (possibly after con-
version from fibrillation to flutter, also favored by
these drugs), and in the absence of sufficient
AV nodal blocking effect, each atrial activation may
conduct to the ventricles. AV nodal conduction is
more rapid for a slower atrial arrhythmia due to
AV nodal refractoriness properties. This is one of
the main concerns with the use of IC agents in
a ‘pill in the pocket’ strategy, and means that the
first time the drug is administered it should be done
so in a monitored setting. In Kosior et al. [1] study,
slightly more patients experienced atrial flutter
after propafenone than quinidine, as expected. In
terms of other side effects, the absence of
significantly greater gastrointestinal intolerance
with quinidine (14% vs. 5%, p = NS) suggests a lack
of power in this relatively small study.
Propafenone converted atrial fibrillation to si-
nus rhythm in a more timely fashion than quinidine,
83.3% vs. 54.3% at 8-hours after drug initiation.
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Does this favor widespread adoption of this in-pa-
tient strategy for conversion? It is not clear if the
8-hour cutoff was a preselected endpoint or if
24 hours or another time point was the initial ob-
jective. If not preselected, the finding of a differ-
ence at 8-hours is less important.
In many health systems, such patients with
new onset atrial fibrillation would be treated with
cardioversion and discharged, especially if the atrial
fibrillation was recurrent, rather than a first onset,
and as long as significant heart failure or other
symptoms were absent. This approach may be more
expeditious than the prolonged observation period
necessary with a QT prolonging drug. The ‘pill in
the pocket’; approach, on the other hand, for eligible
patients with recurrent atrial fibrillation is another
strategy to minimize the need for hospitalization.
In cases where inpatient pharmacological con-
version is required, additional intravenous options
include the Ikr blocker Corvert® (ibutilide fumarate
[Corvert]) which carries a non-trivial rate of tor-
sades at 3.9% [5]. Under development are intrave-
nous agents which block the predominantly atrial
IKur channels and therefore do not prolong the QTc
or cause torsades as often. Another caveat related
to pharmacological conversion not stressed in this
publication is the need for anticoagulation in cases
where the atrial fibrillation duration is greater than
24–48 hours, or is uncertain. The authors limited
the study to patients with atrial fibrillation less than
48 hours. In many cases there is a lack of reliability
of the patient’s history (due to asymptomatic atrial
fibrillation in essence) or certainty that makes an-
ticoagulation and a delayed cardioversion or alter-
natively a transesophageal echocardiogram neces-
sary for early cardioversion (pharmacological or
electrical).
In summary, the quinidine vs. propafenone
publication expands our knowledge base and ex-
perience with these agents, confirms a tendency
toward superiority of the newer agent and of
course calls for more data on the safe and expedi-
tious management of new onset, or recurrent, atrial
fibrillation.
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